NIKKEI 225
38,617.10 -329.83 (-0.85%) HANG SENG
19,195.60 -25.02 (-0.13%) CRUDE OIL
77.50 -1.16 (-1.47%) GOLD FUTURES
2,391.10 -34.80 (-1.43%) DOW
39,675.66 -197.33 (-0.49%) Bitcoin GBP
54,706.61 -73.85 (-0.13%)
BMY Jan 2026 45.000 put
| Previous close | 6.53 |
| Open | 6.57 |
| Bid | 6.40 |
| Ask | 6.70 |
| Strike | 45.00 |
| Expiry date | 2026-01-16 |
| Day's range | 6.57 - 6.70 |
| Contract range | N/A |
| Volume | |
| Open interest | 5.43k |
ReutersBristol Myers, Sanofi liability in Hawaii Plavix case grows to $916 million
A judge in Hawaii on Tuesday ordered Bristol Myers Squibb and Sanofi to pay more than $916 million to the state for failing to warn non-white patients of health risks from its blood thinner Plavix, up from an earlier judgment of $834 million. The ruling from Judge James Ashford, of Hawaii's First Circuit Court, follows a non-jury trial held last fall. It was the second trial in the case, after the state's Supreme Court found that the judge in the first trial that resulted in the $834 million award had made a legal error.
Business WireBristol Myers Squibb Announces 10-Year Strategy to Reach More Patients in Low- and Middle-Income Countries
PRINCETON, N.J., May 22, 2024--Bristol Myers Squibb Announces 10-Year Strategy to Reach More Patients in Low- and Middle-Income Countries
PR NewswireNeoPhore closes oversubscribed Series B extension round with additional funding from Bristol Myers Squibb
NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announces that Bristol Myers Squibb (NYSE: BMY) has joined its oversubscribed Series B extension round.
